U.S. Markets closed

ChemoCentryx to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., May 30, 2018 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences in June:

  • Jefferies 2018 Global Healthcare Conference
    Corporate Overview: Friday, June 8, 2018 at 9:30 a.m. ET.
    Grand Hyatt New York Hotel, New York, NY
  • JMP Securities 2018 Life Sciences Conference
    Fireside Chat Discussion: Wednesday, June 20, 2018 at 10:30 a.m. ET.
    The St. Regis New York Hotel, New York, NY

Live audio webcasts of the presentations can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. Replays of the webcasts will be available on the Company's website for two weeks following each live presentation.

About ChemoCentryx

ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx is currently focusing on its late stage drug candidates for patients with rare diseases, avacopan (CCX168) and CCX140.

Avacopan is an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor, or C5aR. Avacopan is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (ANCA-associated Vasculitis). In clinical studies to date, avacopan was shown to be safe and well tolerated and provided effective control of the disease while allowing elimination of high-dose steroids, part of the current standard of care. ChemoCentryx is also developing avacopan for the treatment of patients with C3 glomerulopathy (C3G), hidradenitis suppurativa (HS), and atypical hemolytic uremic syndrome (aHUS). The U.S. Food and Drug Administration has granted avacopan orphan-drug designation for ANCA-associated Vasculitis, C3G and aHUS. The European Commission has granted orphan medicinal product designation for avacopan for the treatment of two forms of ANCA-associated Vasculitis: microscopic polyangiitis and granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis), as well as for C3G. Avacopan was also granted access to the European Medicines Agency's (EMA) PRIority MEdicines (PRIME) initiative, which supports accelerated assessment of investigational therapies addressing unmet medical need.

The Company's other late stage drug candidate is CCX140, an inhibitor of the chemokine receptor known as CCR2, which is currently being developed for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease.

ChemoCentryx's Kidney Health Alliance with Vifor Pharma provides Vifor Pharma with exclusive rights to commercialize avacopan and CCX140 in markets outside of the U.S. and China.

ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Source: ChemoCentryx, Inc.
CCXI-G

Contacts:

Susan M. Kanaya                                                          
Executive Vice President,                                                           
Chief Financial and Administrative Officer
investor@chemocentryx.com                                          

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com

Investors:
Steve Klass, Burns McClellan
212.213.0006                
sklass@burnsmc.com